Edwin Parrilla, MD
General Practice · Royal Palm Beach, FLNPI 1710306642
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 447 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Novo Nordisk at 25.1% of the total. Reporting peaked in 2019 at $2,870 and has fallen 94.2% since, to $166 in 2025. Among general practice clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 447 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- Lilly USA, LLC$1K
- Amgen$1K
- Pfizer$731
- AstraZeneca$692
- GSK$657
- plus $4K from 17 others
Across 10 payments — averaging $5644.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$56K
What the payments were for
- Food & beverage$10,350100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 111 | $2,598 |
| Lilly USA, LLC | 60 | $1,104 |
| Amgen(2 entities) | 38 | $1,029 |
| Pfizer | 41 | $731 |
| AstraZeneca | 27 | $692 |
| GSK | 35 | $657 |
| Boehringer Ingelheim | 33 | $647 |
| AbbVie(2 entities) | 29 | $571 |
| Bayer | 11 | $451 |
| Amarin Pharma, Inc. | 8 | $420 |
| Merck | 14 | $301 |
| Novartis | 12 | $289 |
| Galderma Laboratories, L.p. | 3 | $262 |
| Abbott | 4 | $196 |
| Esperion Therapeutics, Inc. | 11 | $171 |
| E.r. Squibb & Sons, L.L.C. | 1 | $111 |
| Jazz Pharmaceuticals Inc. | 3 | $41 |
| Johnson & Johnson | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Merz North America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,367 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 59 | $83,184 |
| JardianceEmpagliflozin | 41 | $54,518 |
| MounjaroTirzepatide | 36 | $51,916 |
| EliquisApixaban | 47 | $40,203 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $35,357 |
| FarxigaDapagliflozin Propanediol | 30 | $30,243 |
| TrulicityDulaglutide | 29 | $27,410 |
| XareltoRivaroxaban | 21 | $21,775 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $15,917 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $15,552 |
| EntrestoSacubitril/Valsartan | 11 | $14,825 |
| LinzessLinaclotide | 21 | $14,637 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $6,958 |
| Sirolimus | 12 | $3,939 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,598 | $83,18459 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,104 | $79,32665 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat | $647 | $77,02870 claims |
| PfizerEliquis | $731 | $40,20347 claims |
| GSKTrelegy Ellipta | $657 | $35,35739 claims |
| AstraZenecaFarxiga | $692 | $30,24330 claims |
| Johnson & JohnsonXarelto | $23 | $21,77521 claims |
| NovartisEntresto | $289 | $14,82511 claims |
| AbbVieLinzess | $571 | $14,63721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Royal Palm Beach
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
- Sarah JockinTampa$308K
- Mario RomeroSarasota$275K
- Robert RitterJupiter$233K
- Robert AltharPensacola$231K
- Florencia ZiemkeWest Palm Beach$208K
- Ausberto HidalgoPembroke Pines$171K
- Rickie FergusonPembroke Pines$170K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.